Helicobacter pylori Eradication Leads to Improvement in Rosacea

Overall, 150 of 167 patients received <i>H pylori</i> eradication therapy, with a 92% cure rate.
Overall, 150 of 167 patients received H pylori eradication therapy, with a 92% cure rate.

HealthDay News — For patients with concurrent rosacea and Helicobacter pylori infection, use of standard H pylori eradication therapy is associated with improvement in rosacea, according to a study published in the Journal of Dermatology.

Parviz Saleh, MD, from the Tabriz University of Medical Sciences in Iran, and colleagues examined the effect of standard eradication of H pylori on the clinical course of rosacea in a single-arm trial. Patients ascertained to have H pylori infection based on serological studies were assessed for rosacea. Patients with concurrent rosacea and H pylori infection were recruited and treated with standard H pylori eradication therapy. At the start of the trial, 2 months later, and at day 180 (end of the trial), rosacea was evaluated using the Duluth rosacea grading score.

A total of 19.15% of the 872 patients positive for H pylori manifested the clinical features of rosacea. The researchers found that compared with rosacea-free patients, patients with concurrent rosacea were younger (P <.001), with female sex predominance (=.03). Overall, 150 of 167 patients received H pylori eradication therapy, with a 92% cure rate. On day 0, 60 and 180, the rosacea Duluth score grading decreased significantly among patients cured of H pylori infection in most of the criteria, except for telangiectasia (=.712), phymatous changes (=.535), and the existence of peripheral involvement (=.431).

"The present study concluded that H pylori eradication leads to improvement of rosacea," the researchers write.

Reference

Saleh P, Naghavi-Behzad M, Herizch H, Mokhtari F, Mirza-Aghazadeh-Attari M, Piri R. Effects of helicobacter pylori treatment on rosacea: a single-arm clinical trial study [published online April 28, 2017]. J Dermatol. doi: 10.1111/1346-8138.13878.

You must be a registered member of Infectious Disease Advisor to post a comment.

Sign Up for Free e-newsletters